Prevalence and coexistence of type 2 inflammatory diseases
Autor/a
Fecha de publicación
2024ISSN
2045-7022
Resumen
Background: Type 2 inflammation has been described as a pathophysiological basis common to some diseases, such as atopic dermatitis (AD), chronic rhinosinusitis with nasal polyps, and asthma (CRSwNP). Objective: The present study used population-based prevalence in Catalonia to analyse the coexistence of type 2 inflammatory diseases in patients primarily diagnosed with the above mentioned conditions. Results: We found a high degree of coexistence of type 2 inflammatory diseases among these patients, with the prevalence being higher in the severe forms, except for AD. For the severe forms of primary diseases, the proportion of patients with coexisting type 2 inflammatory diseases (severe or non-severe) was 16.2% for AD, 19.8% for asthma, and a striking 62.4% for CRSwNP. This patient population has the highest proportion of coexisting type 2 inflammatory diseases, both severe (48.9%) and non-severe (13.5%). Conclusion: Our findings have significant implications for the management of patients with AD, asthma, and CRSwNP.
Tipo de documento
Artículo
Versión del documento
Versión publicada
Lengua
Inglés
Materias (CDU)
61 - Medicina
616.2 - Patología del aparato respiratorio
Palabras clave
Páginas
4
Publicado por
Wiley
Colección
14; 6
Publicado en
Clinical and Translational Allergy
Citación
Mora, Toni; Sánchez-Collado, Irene; Muñoz‐Cano, Rosa [et al.]. Prevalence and coexistence of type 2 inflammatory diseases. Clinical and Translational Allergy, 2024, 14(6), e12376. Disponible en: <https://onlinelibrary.wiley.com/doi/10.1002/clt2.12376>. Fecha de acceso: 16 dic. 2024. DOI: 10.1002/clt2.12376
Nota
Sanofi; University of Catalonia Real‐WordEvidence Chair
Este ítem aparece en la(s) siguiente(s) colección(ones)
Derechos
This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, pro-vided the original work is properly cited.© 2024 The Author(s). Clinical and Translational Allergy published by John Wiley & Sons Ltd on behalf of European Academy of Allergy and Clinical Immunology.
Excepto si se señala otra cosa, la licencia del ítem se describe como https://creativecommons.org/licenses/by/4.0/


